Altered Oncogene Activity Contributes to Compensation for Antisense Suppression of BCL-2 and Tumor Resistance

Open Journal of Apoptosis
doi 10.4236/ojapo.2015.43007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Scientific Research Publishing, Inc,

Related search

miR-15b Suppression of BCL-2 Contributes to Cerebral Ischemic Injury and Is Reversed by Sevoflurane Preconditioning

CNS and Neurological Disorders - Drug Targets
MedicineNeurosciencePharmacology
2013English

In LNCaP Cells Enhanced Expression of the Androgen Receptor Compensates for BCL-2 Suppression by Antisense Oligonucleotides

Therapeutic Advances in Urology
Urology
2011English

In LNCaP Cells Enhanced Expression of Both Androgen Receptor and Costimulatory Protein P300 Compensate for Antisense Oligonucleotide Suppression of BCL-2

Therapeutic Advances in Urology
Urology
2011English

Local Angiotensin II Contributes to Tumor Resistance to Checkpoint Immunotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Contribution of BCL-2 Phosphorylation to Bak Binding and Drug Resistance

Cancer Research
Cancer ResearchOncology
2013English

Nitric Oxide Promotes Resistance to Tumor Suppression by CTLs

Journal of Immunology
AllergyImmunology
2006English

The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

WL-276, an Antagonist Against BCL-2 Proteins, Overcomes Drug Resistance and Suppresses Prostate Tumor Growth

Cancer Research
Cancer ResearchOncology
2008English

Long Non-Coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy